Evidence that matters for your situation

Immunotherapy Overview

Before you start comparing providers or prices, first check whether your cancer type, stage, biomarkers and treatment history actually match an established immunotherapy pathway.

Checkpoint inhibitorsEstablished in many defined cancer settings.

CAR T and selected cell therapiesEstablished for specific indications and patient groups.

Many NK-cell approachesStill investigational, especially across solid tumors.

Check What Fits My Situation Talk Before I Decide

What the label doesn’t tell you

The treatment name is not enough. The indication matters.

The same word “immunotherapy” can describe a standard drug, an approved cellular therapy, or an experimental approach. Evidence must match the exact cancer and treatment setting.

Checkpoint inhibitors

PD-1, PD-L1, CTLA-4 and related checkpoint drugs have established roles in many cancers. The drug, stage, biomarker and treatment line still have to match.

Established uses

CAR T-cell therapy

Used for selected blood cancers. The pathway can include cell collection, manufacturing, lymphodepletion, infusion and close monitoring for serious toxicities.

Selected cancers

TIL and other T-cell therapies

Tumor-infiltrating lymphocyte therapy has an approved use in a defined melanoma setting in the United States. Other T-cell approaches have different evidence and regulatory status.

Defined use

NK-cell therapies

NK cells have real anti-tumor biology and are being studied in clinical programs. For many solid-tumor uses, a proven survival advantage has not been established.

Often investigational

Eligibility check

What decides whether immunotherapy may fit your case?

Pathology and current stageThe exact cancer subtype, where it has spread, and whether disease is resectable can change the treatment pathway.
Previous treatment and responseSurgery, chemotherapy, radiation, targeted therapy and previous immunotherapy can determine what remains reasonable next.
Biomarkers that matter for that cancerExamples include PD-L1, MSI or mismatch-repair status, tumor mutational burden, BRAF and therapy-specific cell targets such as CD19 or BCMA.
Safety factorsAutoimmune disease, organ transplant, lung or heart disease, active infection, liver and kidney function, blood counts and steroid use may affect risk.
Performance status and urgencySome cell therapies need time for collection or manufacturing. Rapidly progressing disease may change what is practical.

A positive biomarker doesn’t guarantee anything. It can raise the odds that a therapy will be considered in some settings, but on its own, it won’t predict your individual result.

What to confirm, cancer by cancer

The useful question is what needs to be confirmed in your diagnosis.

Cancer settingCommonly relevant informationWhy it matters

Non-small cell lung cancerPD-L1, driver mutations, stage, prior systemic therapyCheckpoint therapy can be used alone or in combinations in defined settings, while actionable driver mutations can change first treatment choices.

MelanomaStage, resectability, BRAF status, prior PD-1 therapyCheckpoint therapy is established; selected patients may have other cellular options after previous treatment.

Colorectal or endometrial cancerMSI and mismatch-repair status, stage, prior therapyMSI-high or mismatch-repair-deficient tumors can be particularly important when considering checkpoint therapy.

Kidney, bladder, head and neck, gastric and other cancersStage, pathology, prior therapy, selected biomarkersImmunotherapy may be part of standard care in defined settings, but the regimen and sequence differ by cancer.

Leukemia, lymphoma and myelomaExact subtype, target expression, prior lines of therapy, transplant historyCAR T and other immune-based treatments are indication-specific and require detailed treatment history.

These are examples for discussion, not a treatment recommendation. Approved indications differ by country and change over time.

Not sure which information applies to you?

Send what you already have. A complete file is not required to start organizing the next questions.

See What I Should Prepare Talk Through My Situation

What the survival data actually shows

There is no single immunotherapy survival rate.

A survival number only makes sense with its cancer type, stage, biomarker, treatment line and regimen. These trial results show how different the answer can be.

31.9%5-year overall survival

Metastatic NSCLC with PD-L1 TPS at least 50%

In KEYNOTE-024, first-line pembrolizumab had an estimated five-year overall survival of 31.9% versus 16.3% with chemotherapy in the trial population. This does not apply to every lung cancer patient.

KEYNOTE-024, Journal of Clinical Oncology

43%10-year overall survival

Advanced melanoma in CheckMate 067

At ten years, overall survival was 43% with nivolumab plus ipilimumab, 37% with nivolumab, and 19% with ipilimumab. Long survival in a trial population is not a guarantee of cure for an individual patient.

CheckMate 067, New England Journal of Medicine

42.6%5-year overall survival

Refractory large B-cell lymphoma after axi-cel CAR T

In the single-arm ZUMA-1 follow-up, the estimated five-year overall survival was 42.6%. Because there was no randomized comparison in this study, this number should not be used as a direct comparison with another treatment.

ZUMA-1 five-year follow-up, Blood

Response rate, progression-free survival and overall survival don’t measure the same thing. A shrunken tumor on a scan doesn’t automatically mean the treatment improves how long you’ll live.

Safety: it changes with the type

The risk profile changes with the type of immunotherapy.

Checkpoint inhibitorsFatigue, rash and diarrhea can occur. Immune-related inflammation can also affect the lungs, liver, bowel, thyroid, pituitary, kidneys, heart or nervous system.

CAR T-cell therapyCytokine release syndrome, neurologic toxicity, infection and prolonged low blood counts can require close monitoring and urgent treatment.

TIL and intensive cell therapyRisks can come from the cell product and from the surrounding regimen, including lymphodepleting chemotherapy, infection risk and organ stress.

After treatmentFollow-up can include blood tests, imaging and monitoring for delayed immune effects. Some immune-related problems may continue after treatment stops.

Don’t wait for online coordination if symptoms feel severe or they’re getting worse fast. Breathing trouble, chest pain, confusion, severe weakness, a fever that won’t break, or major diarrhea may all need immediate local medical care.

NK-cell evidence

What should you verify before paying for NK-cell therapy?

The key issue is not whether NK cells can kill cancer cells in a laboratory. The question is whether the exact product and protocol have clinical evidence for your cancer.

Read: NK Cell Therapy in Japan

Ask for the exact evidence levelSeparate laboratory findings, early-phase safety studies, response data and randomized survival evidence. They answer different questions.

Ask what the cell count actually representsA large number of infused cells does not by itself prove better tumor control. Cell function, persistence, tumor access and the clinical protocol also matter.

Ask whether it is replacing standard careFor many solid tumors, NK-cell approaches remain investigational. Stopping established therapy should only be considered with the treating oncology team.

Check the regulatory status of the exact product“Cell therapy,” “regenerative medicine” and “approved medicine” are not interchangeable terms. Regulatory status should be confirmed for the country, product and indication.

Ask how success will be measuredBefore starting, clarify the scan schedule, blood tests, clinical endpoints and what would count as progression, stable disease or response.

Cost planning in Japan

A useful price starts with the exact treatment pathway.

A single advertised number can leave out testing, hospitalization, imaging, side-effect management or the difference between insured and self-pay care.

Medical imaging example used when planning the testing, monitoring and cost of an immunotherapy pathway

What changes the estimate

Confirm the exact therapy

Drug name or cell product, treatment line, dose or number of cycles, and whether the treatment is approved for that use.

Add the required testing

Pathology review, biomarkers, blood tests, imaging and organ-function tests may be priced separately from the treatment itself.

Include monitoring and adverse-event care

Infusion care, inpatient observation, repeat scans, laboratory monitoring and management of complications can materially change the final total.

Check the payment pathway

Public insurance, private insurance, self-pay care and investigational treatment can create very different out-of-pocket costs.

Japan cost checkpoints

For people enrolled in Japanese public insurance

Japan’s High-Cost Medical Expense Benefit can limit eligible monthly insured copayments based on the patient’s income bracket and the charges that qualify under the system. It does not cover every charge or every uninsured service.

For international or self-pay patients

Ask for an itemized estimate before travel. Confirm what is included, what is excluded, when payment is due, and how extra costs are handled if more testing or monitoring becomes necessary.

Ask for these line items in writing

Drug or cell product charges
Biomarker testing and pathology review
Imaging, blood tests and organ-function checks
Day treatment or hospitalization fees
Monitoring, emergency care and follow-up scans

Check What Applies to Me Ask About My Next Step

What to send first

A diagnosis name alone is usually not enough.

The goal is to organize enough information for the next question to be specific, without asking you to repeat the whole medical process from the beginning.

Priority records

Pathology report with the exact cancer diagnosis
Latest CT, MRI or PET-CT report
Current stage and known metastatic sites
Previous treatment names and dates
Most recent treatment response or progression

Useful when available

PD-L1, MSI or mismatch-repair results
Genomic or mutation testing reports
Recent blood counts, liver and kidney tests
Autoimmune or transplant history
Current medicines, including steroids

We organize what you already have

We collect the preliminary information and identify missing items that may be needed before the next appointment request.

We coordinate the next appointment step

Once enough information is available, we support appointment coordination and help keep the request focused on the questions you need answered.

We support medical translation

We help make records, questions and explanations easier to follow across languages so important details are less likely to be lost.

We’re not a hospital or clinic. We don’t diagnose cancer, prescribe treatment or guarantee eligibility or outcomes. Medical decisions stay with the treating medical team.

What to plan before you get on the plane

What should be clear before you travel?

Response checkWhen is the first scan or blood test, and which findings will be used to judge response or progression?

Safety planWhich symptoms require urgent care, and who manages immune-related or cell-therapy side effects after you return home?

Local follow-upWhat information should be given to your local oncology team, and which tests can be completed at home?

Travel timingHow long should you remain nearby after treatment, especially if the pathway includes cell therapy or intensive monitoring?

Plan if it does not workWhat is the next option if scans show progression, side effects require stopping, or the intended therapy is not suitable?

Related patient resourcesUse the next page that matches the question you still need to answer.

NK Cell Therapy in JapanEvidence and practical questions Immunotherapy in JapanJapan-focused overview Precision Cancer CheckupImaging and diagnostic review Advanced Health ScreeningTesting and screening options

Questions worth asking before you decide

Questions that change the decision.

A useful answer should be specific to your diagnosis and should clearly separate established treatment from research-stage options.

Medical imaging example used when discussing questions patients may ask before an immunotherapy decision

Can immunotherapy cure cancer?

Some patients in specific settings have durable long-term responses, but immunotherapy is not a universal cure. Published survival data are population results, not an individual forecast.

What if I already failed a PD-1 drug?

The next step depends on the cancer, prior combinations, biomarkers and available approved options or trials. Switching to another immune approach is not automatically beneficial.

Can I use NK cells instead of chemotherapy or surgery?

Not as a general rule. For many solid tumors, NK-cell approaches remain investigational. Replacing standard care requires disease-specific evidence and an oncology decision.

Does a higher immune-cell count mean a better result?

No. Cell number is only one manufacturing detail. Clinical benefit also depends on cell function, persistence, tumor biology, the treatment protocol and the quality of evidence.

How soon should I expect a scan result?

Timing varies by disease and regimen. Scans are usually scheduled at defined intervals, and early imaging should be interpreted with symptoms, blood tests and prior scans rather than judged alone.

Can autoimmune disease rule immunotherapy out?

It can change the risk and may affect treatment selection, but the answer is not the same for every autoimmune condition. The disease activity, medicines and intended regimen need individual review.

What do you do for international patients?

We help collect preliminary information, coordinate appointment requests and support medical translation. We do not provide diagnosis, prescribing or treatment decisions.

Selected evidence sources

NCI: Immunotherapy to Treat Cancer NCI: Immune Checkpoint Inhibitors NCI: Immunotherapy Side Effects FDA: Approved Cellular and Gene Therapy Products PMDA: Regenerative Medical Products MHLW: High-Cost Medical Expense Benefit

Support for patients coming from abroad

Start with the records you already have.

Send your diagnosis, latest imaging report and treatment history. We can help organize the information, clarify what may still be missing, coordinate the next appointment step and support medical translation.

Send What I Already Have Help Me Figure Out the Next Step

Educational information only. It doesn’t diagnose cancer, determine eligibility or predict outcomes. If symptoms are severe or getting worse fast, you need local urgent medical care-not online coordination.